We would love to hear your thoughts about our site and services, please take our survey here.
It hasn't gone unnoticed that members of the BoD collectively invested around £135k just a couple of months ago, and at a much higher price than we have today.
Together with the undisclosed shareholding of the brilliant Bhavika Patel, I am in no doubt that this is a winner.
Let's see what tomorrow brings.
Today's results exceeded most expectations, and as a recent shareholder I'm well pleased.
A company producing a sanitizing product is not exactly a glam stock, but I feel that once the market realizes the potential here, we will see a huge increase in share price.
The stock market media will now be evaluating this news, and will no doubt be commenting in due course.
I've noticed that one of the Winnifroth crew have mentioned us in the past, so here's hoping his keyboard contributions will give us more exposure to this great investment opportunity and put us above the radar.
No doubt this stitch up is sharia compliant
YGEN under the radar
TIDMYGEN
RNS Number : 3042B
Yourgene Health PLC
07 October 2020
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
IONA (R) Nx awarded contract with St George's NHS Hospital
Manchester, UK - 7 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has been awarded the contract for non-invasive prenatal testing (NIPT) using its newly-launched IONA (R) Nx NIPT Workflow ('IONA(R) Nx'), by the prestigious St George's NHS Trust Foundation in Tooting, South London ("St George's"). The contract, subject to signing by both parties, has been awarded after a competitive tender process and will extend Yourgene's existing partnership with St George's for a further three years, with testing volumes expected to increase over the contract period.
St George's was the first NIPT NHS laboratory in the UK and the first NHS Trust to provide NIPT testing to high risk pregnant women. St George's has a reputation for innovation in NIPT introducing these tests well ahead of the National Screening committee's January 2016 recommendation to do so. Yourgene won its first tender with St George's on 23 March 2015 with the Company's IONA (R) test to provide NIPT testing for women within South East England and to other NHS trusts and private practices across the UK.
Since that first tender, the lab has been offering the IONA (R) test under the St George's brand of the SAFE test. The new contract will see St George's transition over to the IONA(R) Nx NIPT Workflow which has been developed to run on the Illumina NextSeq 550Dx instrument.
Lyn Rees, CEO of Yourgene, commented: "We were chosen out of five companies that bid for the tender; I believe this is a true reflection of the excellent service and continued support that Yourgene offers its customers. The team at St George's have been early adopters and true champions of the benefits of NIPT for all pregnant women as part of antenatal screening. We have already been working in close partnership with St George's over the last few years, and look forward to strengthening our relationship with them further over the next few years."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore
The first RNS worried me, but the correction is encouraging
It's only just begun!
Set an example, Dan - spread the news to your Covid friends
Mark Henderson and the BoD have told bare faced lies in presentations and RNSs - how you can possibly deny that defies logic.
Your admiration of Bobo is commendable, but your concluding comment regarding 'wives and girlfriends' I find nauseous and somewhat condescending.
Having said that, it's reassuring to know that we have a 'man of action' in our midst.
Covid testing is not our main source of income - NIPT is the jewel in the crown, as I was reminded of just a few days ago by someone who knows all there is to know about this company!
I'm one of the unknown buyers this morning
Don't be dismayed by all the red trades shown here today, as most of them were buys.
I could have doubled my holding today at 18.88p., but I think I'll wait . . . . . . .
Thanks for your support - buddy ??
And only a few days ago I was rebuked in an offensive manner for posting a link to covid testing, and I was reminded that the core business was NIPT!
I think that poster owes me an apology.
I couldn't agree more, Hickson.
When the herd cotton on to us we can expect fireworks
Not for a moment do I believe that all those big red trades were sells.
Whoever is in charge of the bid and ask display shown here is up to some manipulative mischief.
??
A £44k. buy is certainly a vote of confidence
Please don't apologize.
If you're unaware of COVID and the testing and diagnosis of the same, may I suggest that you're also unaware of the involvement of YGEN in this area.
If you can't see a related interest I think you have a problem.
9.15am: TT Electronics jumps on launch of new saliva-based coronavirus test
TT Electronics PLC (TTG) shares shot 39% higher to 266p in early trading on Thursday after the company said it will be the exclusive manufacturer of a new coronavirus (COVID-19) screening device.
Designed by British start-up iAbra, with the support of chip giant Intel, the Virolens device uses microscopic holographic imaging and artificial intelligence software to detect the presence of the COVID-19 virus from a non-intrusive saliva swab test within 20 seconds.
TT said it has so far received £2mln of initial orders for the device and testing cartridges and iAbra has indicated its intent to purchase further devices and cartridges with associated revenue to TT of circa £280mln, following trials in partnership with initial customer Heathrow Airport ahead of expected wider use in airports, offices, sports venues and other locations.
Heathrow boss John Holland Kaye said iAbra’s test is “quicker, cheaper and potentially more accurate” than the government’s swab test and urged the government to fast-track the technology.